S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in

Esperion Therapeutics Stock Forecast, Price & News

+0.48 (+1.89 %)
(As of 01/22/2021 12:00 AM ET)
Today's Range
Now: $25.93
50-Day Range
MA: $28.38
52-Week Range
Now: $25.93
Volume929,329 shs
Average Volume915,025 shs
Market Capitalization$722.85 million
P/E RatioN/A
Dividend YieldN/A
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
Esperion Therapeutics logo


Overall MarketRank

1.22 out of 5 stars

Medical Sector

791st out of 1,923 stocks

Pharmaceutical Preparations Industry

396th out of 773 stocks

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ESPR



Sales & Book Value

Annual Sales$148.36 million
Book Value$0.73 per share


Net Income$-97,170,000.00


Market Cap$722.85 million
Next Earnings Date2/25/2021 (Estimated)
+0.48 (+1.89 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ESPR News and Ratings via Email

Sign-up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Esperion Therapeutics (NASDAQ:ESPR) Frequently Asked Questions

How has Esperion Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Esperion Therapeutics' stock was trading at $42.93 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ESPR stock has decreased by 39.6% and is now trading at $25.93.
View which stocks have been most impacted by COVID-19

Is Esperion Therapeutics a buy right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Esperion Therapeutics stock.
View analyst ratings for Esperion Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Esperion Therapeutics?

Wall Street analysts have given Esperion Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Esperion Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Tim Mayleben's approval rating as Esperion Therapeutics' CEO?

20 employees have rated Esperion Therapeutics CEO Tim Mayleben on Glassdoor.com. Tim Mayleben has an approval rating of 80% among Esperion Therapeutics' employees.

When is Esperion Therapeutics' next earnings date?

Esperion Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Esperion Therapeutics

How were Esperion Therapeutics' earnings last quarter?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) released its earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($3.07) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($3.52) by $0.45. The biopharmaceutical company had revenue of $3.83 million for the quarter, compared to analysts' expectations of $4.04 million. Esperion Therapeutics had a negative trailing twelve-month return on equity of 629.88% and a negative net margin of 46.15%. The company's revenue was up 290.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($2.52) earnings per share.
View Esperion Therapeutics' earnings history

What price target have analysts set for ESPR?

12 equities research analysts have issued twelve-month price targets for Esperion Therapeutics' shares. Their forecasts range from $35.00 to $191.00. On average, they expect Esperion Therapeutics' share price to reach $79.08 in the next twelve months. This suggests a possible upside of 205.0% from the stock's current price.
View analysts' price targets for Esperion Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Esperion Therapeutics' key competitors?

What other stocks do shareholders of Esperion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include (ALDW) (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), SFL (SFL), Gilead Sciences (GILD), The Boeing (BA), Alibaba Group (BABA) and BioMarin Pharmaceutical (bmrn).

Who are Esperion Therapeutics' key executives?

Esperion Therapeutics' management team includes the following people:
  • Mr. Timothy M. Mayleben M.B.A., Pres, CEO & Director (Age 60, Pay $1.08M)
  • Mr. Richard B. Bartram, CFO & Corp. Sec. (Age 39, Pay $485.5k)
  • Mr. Sheldon L. Koenig, Chief Operating Officer (Age 55)
  • Dr. Kenneth J. Fiorelli, Chief Technical Operations Officer
  • Mr. Benjamin Church, Head of Corp. Communications & Investor Relations
  • Mr. Keith F. Lenden, VP of Corp. Devel. & Strategy (Age 48)
  • Renee Marotta, Head of Marketing
  • Ms. Ashley Hall, Chief Devel. Officer (Age 49)
  • Ms. April Seiler, Sr. Director of Project Management
  • Roberta Peterson, Sr. Director of National Accounts

What is Esperion Therapeutics' stock symbol?

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

Who are Esperion Therapeutics' major shareholders?

Esperion Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (2.12%) and Pacer Advisors Inc. (0.02%). Company insiders that own Esperion Therapeutics stock include Nicole Vitullo, Richard Bartram, Roger S Newton, Target N V Biotech and Timothy M Mayleben.
View institutional ownership trends for Esperion Therapeutics

Which institutional investors are buying Esperion Therapeutics stock?

ESPR stock was purchased by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, and Pacer Advisors Inc.. Company insiders that have bought Esperion Therapeutics stock in the last two years include Target N V Biotech, and Timothy M Mayleben.
View insider buying and selling activity for Esperion Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Esperion Therapeutics?

Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Esperion Therapeutics' stock price today?

One share of ESPR stock can currently be purchased for approximately $25.93.

How big of a company is Esperion Therapeutics?

Esperion Therapeutics has a market capitalization of $722.85 million and generates $148.36 million in revenue each year. The biopharmaceutical company earns $-97,170,000.00 in net income (profit) each year or ($3.59) on an earnings per share basis. Esperion Therapeutics employs 193 workers across the globe.

What is Esperion Therapeutics' official website?

The official website for Esperion Therapeutics is www.esperion.com.

How can I contact Esperion Therapeutics?

Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company can be reached via phone at 734-887-3903 or via email at [email protected]

This page was last updated on 1/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.